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Abstract. Iron deficiency and Plasmodium falciparum malaria are the two main causes of anemia in young children
in region endemic for this disease. The impact on iron status of prophylactic oral iron supplementation (2 mg/kg/day
from two to six months of age) and the duration of this effect were assessed in a group of 832 Tanzanian infants exposed
to P. falciparum malaria. Iron parameters and red blood cell indices were assessed at 2, 5, 8, and 12 months of age. Infants
who received iron supplements had a significantly lower prevalence of iron deficiency (P < 0.01 at 5 months and P < 0.001
at 8 and 12 months). Red blood cell indices (mean corpuscular volume, mean cell hemoglobin, and mean cell hemoglobin
concentration) were increased in children receiving iron supplementation and they did not differ between those pro-
tected and unprotected against malaria. The prevalence of ferropenia was similar in children protected against malaria
and in those who were not protected and did not receive iron supplements (34.7% versus 37.3% at 12 months of age).
We concluded that iron supplementation between the ages of 2−6 months improves iron status at least up to 12 months
of age. Malaria infection does not contribute to iron deficiency.
INTRODUCTION
The burden of anemia on mortality and morbidity world-
wide is difficult to quantify, but community prevalence figures
reach 90% of the children being anemic in some sub-Saharan
countries. Severe anemia in young children is one of the main
reasons for admission to hospitals in many African countries,
where it imposes a great demand on already limited re-
sources. Malaria infection and iron deficiency, especially dur-
ing the first year of life, are the two main causes of anemia in
young children in malaria endemic areas.1−3
The high prevalence of iron deficiency4 in infants in devel-
oping countries is explained mainly by an inadequate iron
intake, poor iron stores as a result of low birthweight, defi-
cient maternal iron stores, and frequent infections.5,6 Despite
guidelines recommending the delivery of iron to target
groups, iron supplementation is not common practice in most
developing countries, where iron is administered only for the
management of anemia. The duration of iron supplementa-
tion required to prevent the development of ferropenic ane-
mia in children in developing countries is not clear. Admin-
istration of iron supplements for more than 20 months has
been recommended.7 However, there are major difficulties
related to delivery of the supplements and maintenance of
compliance for such a prolonged period. Assessing the dura-
tion of the effect on iron status of shorter and more feasible
regimens of iron supplementation may be of public health
relevance.
It has been suggested that malaria infection may also con-
tribute to iron deficiency. The observation of an increased
hematologic recovery when iron has been administered after
a malaria episode8,9 may support this notion. Several mecha-
nisms have been proposed for this, including a decreased iron
absorption as a result of physiologic changes and malabsorp-
tion,10,11 reduced appetite,12 sequestration of iron within the
malaria pigment hemozoin,13 and accumulation of iron within
the cells of the reticuloendothelial system as a response to
infection with Plasmodium falciparum.14 Conversely, ad-
equate stores of iron have been found in the bone marrow of
Gambian children with acute malaria attacks.13 It is therefore
not yet clear whether malaria infection contributes to iron
deficiency.
We have previously reported a randomized, placebo-
controlled trial assessing the effects of malaria chemoprophy-
laxis and iron supplementation on anemia and malaria in in-
fants.3 Malaria chemoprophylaxis reduced the incidence of
anemia by approximately 60%, while iron supplementation
reduced this incidence by approximately 30%.3 Here we re-
port the effects of these interventions on the prevalence of
iron deficiency and on red blood cell indices throughout in-
fancy. Within this framework, we have been able to test the
hypothesis that malaria infection contributes to iron defi-
ciency.
MATERIALS AND METHODS
Study area and population. The study was conducted in
1995−1996 in Ifakara in the Kilombero District of the
Morogoro region of southeastern Tanzania. Characteristics of
the study area have been described in detail elsewhere.3 The
population of Ifakara is approximately 55,000 people, with
the majority being subsistence farmers. Malaria transmission
is intense and perennial with an entomologic inoculation rate
in a nearby village of 300 infective bites per person per year.15
Malaria control relies on presumptive treatment of the clini-
cal episode with an antimalarial (chloroquine at the time of
the study). Government medical services in the town during
the study period were limited to the 375-bed St. Francis Des-
ignated District Hospital and its adjacent maternal and child
health clinic.16
Clinical malaria and severe anemia (packed cell volume
[PCV] < 25%) account for 37% and 35% of the admissions in
children between one and five years of age and 44% and 41%
in those less than one year of age2 (Menendez C, unpublished
data). Malaria infection was found to be responsible for ap-
proximately 60% of severe anemia episodes, while iron defi-
ciency accounted for approximately 30% of such episodes.3
The exact etiology of the 10% remaining severe anemia cases
is unknown, although they are likely to be associated with
bacterial and viral infections and micronutrient deficiencies
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other than iron deficiency. Hookworm infections are unlikely
to play an important role as a cause of anemia in this group of
children because 2 (2.4%) of 205 children harbored hook-
worms in the feces in this setting.17
Study design. The study was part of a randomized, pla-
cebo-controlled, intervention trial of malaria chemoprophy-
laxis and iron supplementation for the prevention of malaria
and anemia in infants.3 Eight hundred thirty-two children
were randomized at two months of age to one of four inter-
vention arms: 1) group IP  daily oral iron supplementation
(2.4 mL of ferrous glycine sulfate (2 mg/kg), 25 mg of ferrous
sulfate per 5 mL, Plesmet syrup: Link Pharmaceuticals, Ltd.,
Bellshill, Lanarkshire, United Kingdom) plus weekly placebo;
2) group DP  weekly oral antimalarial chemoprophylaxis
(2.5 mL of Deltaprim, 3.125 mg of pyrimethamine plus 25
mg of dapsone per 5 mL; Wellcome Pty., Kempton Park,
South Africa) plus daily placebo; 3) group PP daily placebo
and weekly placebo; and 4) group DI daily iron and weekly
chemoprophylaxis. Iron supplementation was administered
from two to six months of age while malaria chemoprophy-
laxis was given from 2 to 12 months of age. Bottles containing
iron supplementation were delivered at home by project field
workers at enrollment and a second bottle was delivered two
months later. Mothers administered the daily iron supple-
ments at home. Compliance with supplementation was as-
sessed by measuring the amount of syrup left in the bottle
using a specially designed ruler at each weekly visit when the
antimalarial was administered. Seventy-five percent of the
children took more than 67% of the expected daily doses.
The frequency of both severe anemia and malaria episodes
was assessed through a combination of passive case detection
and cross-sectional surveys. Cross-sectional surveys were car-
ried out at 2, 5, 8, and 12 months of age. At each cross-
sectional visit, finger prick blood samples were collected for
hematologic and biochemical determinations and two thick
and thin blood films were prepared for quantification of
P. falciparum parasitemia and red blood cell morphology.
The axillary temperature was measured and anthropometric
parameters were recorded.
Infants found to have a PCV < 25% at any of the visits were
withdrawn from the study and treated according to hospital
guidelines consisting of a therapeutic course of an anti-
malarial drug plus daily oral iron in treatment doses for two
weeks. Malaria episodes were treated following the Tanza-
nian national guidelines at the time of the study, which con-
sisted of oral chloroquine (25 mg/kg over a three-day period)
for uncomplicated cases or parenteral quinine for severe ma-
laria cases. Blood transfusions were given following strict
guidelines established at the hospital, which consisted of a
PCV < 12% or the presence of signs of respiratory distress
with a PCV < 18%.
The use of a placebo for iron supplements and malaria
chemoprophylaxis was justified in this area of Tanzania for
the following reasons. 1) Although there was some informa-
tion on the prevalence of malaria infection in children in this
area, no information existed with regards to its frequency in
small infants or to its contribution to anemia and general
morbidity. 2) Similarly, there was no information on the
prevalence of iron deficiency in infants nor on its contribution
to anemia in this age group in malaria endemic areas in gen-
eral. 3) The efficacy of both low doses of iron supplementa-
tion and/or malaria chemoprophylaxis to prevent malaria and
anemia in infants was unknown. 4) Finally, neither malaria
chemoprophylaxis nor iron supplementation were (or are
now) used for prevention of malaria and anemia in children
and infants in malaria-endemic areas. This study excluded
anemic children at the time of recruitment and treated those
developing anemia or malaria according to the Tanzanian
national treatment guidelines.
The study was explained to the parents or guardians of the
participating children, their understanding of it was assessed
with a set of standard questions, and written informed con-
sent was obtained. The study received ethical clearance from
the Tanzanian Commission for Science and Technology and
from the Ethical Committee of the Hospital Clinic from Bar-
celona, Spain and adhered to the principles of the Declaration
of Helsinki that governs biomedical research in human sub-
jects.
Laboratory procedures. Blood samples were collected into
microtainers containing EDTA and heparin (Becton Dickin-
son, Franklin Lakes, NJ) and the separated plasma was stored
at −20°C. Variations in the volumes of plasma available pre-
cluded full analysis of all samples collected. Plasma ferritin
was assayed by an immunoradiometric assay (Tandem-R Fer-
ritin; Hybritech, Inc., San Diego, CA). The normal range for
the kit for children of this age was 10−83 ng/mL. Plasma iron
(reference range  11−150 g/dL) was measured colorimet-
rically using the ferrozine method without deproteinization in
a Cobas Mira S analyzer (Roche Diagnostics, Basel, Switzer-
land). Plasma transferrin (reference range 218−347 mg/dL)
was assayed by immunonephelometric methods using re-
agents in a nephelometer model A (Dade Behring, Marburg,
Germany).
Red blood cell indices (mean corpuscular volume [MCV],
mean cell hemoglobin [MCH], mean cell hemoglobin concen-
tration [MCHC], and red blood cell distribution width
[RDW]) were measured on blood collected into microtainers
containing EDTA with a semiautomatic cell counter (Sysmex
F800 microcell counter; TOA Medical Electronics, Kobe, Ja-
pan).
Light microscopes were used to count reticulocytes on thin
blood films stained with methylene blue, prepared at the
cross-sectional visit at 12 months of age in 100 randomly se-
lected children.
Thick and thin blood films were stained with Giemsa for
malaria parasites or with May-Grunwald for red blood cell
morphology, respectively, and read with a light microscope
following standard procedures.18 Briefly, each slide was read
at least twice, and a third reading was done for major discrep-
ancies between the results of the first two readings (either
positive/negative discrepancies or a ratio of the readings
<0.66 or >1.33). The majority reading for positive/negative
discordances or the geometric mean of three positive readings
was taken as the definitive result.
Definitions and statistical methods. Iron deficiency was de-
fined as either 1) a plasma ferritin level < 12 ng/mL (children
between two and five months old) or < 10 ng/mL (between 8
and 12 months old) or 2) a plasma iron level < 11 g/dL and
a transferrin concentration > 347 mg/dL for all ages.19
Microcytosis was defined as an MCV < 77 fl (children be-
tween two and five months old) or < 70 fl (children between
8 and 12 months old). Hypochromia was defined as an MCH
value < 25 pg or an MCHC value < 29 g/L. A low RDW was
defined as value < 39 fl. Reticulocyte counts greater than 1%
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were considered increased according to the reference values
published for infants.20 Severe anemia was defined as a PCV
less than 25%, and a malaria episode as an axillary tempera-
ture  37.5°C plus a P. falciparum asexual parasitemia of any
density.
The red blood cell indices and iron parameters were com-
pared with respect to the placebo-placebo group at each
cross-sectional survey by using linear regression models for
continuous variables. Logistic regression models were used to
compare the prevalence of iron deficiency by intervention
group and cross-sectional visit with respect to the placebo-
placebo group. Analysis was done using Stata Statistical Soft-
ware version 5.0 (Stata Corporation, College Station TX).
RESULTS
Baseline hematologic and iron parameters are shown in
Table 1. There were no statistically significant differences in
any of the variables studied between the four intervention
groups before the interventions started at two months of age.
Eight hundred thirty-two children met the inclusion criteria to
be randomized into one of the four groups. Throughout the
study, 209 children were found to have severe anemia and
were withdrawn from the study interventions. Other reasons
for withdrawal were migration out of the area, parental re-
fusal, and investigators request. There was no difference be-
tween the study groups in the number of children withdrawn
for any of these reasons except for severe anemia. In this case,
significantly more children in the placebo-placebo group had
to be withdrawn and treated than in any of the other three
groups.3
Iron deficiency. The prevalence of iron deficiency by treat-
ment group and cross-sectional survey is shown in Table 2.
The statistical analysis was based only on those children who
had each result and no attempt was made to predict missing
values.
The prevalence of iron deficiency increased throughout the
first year of life. There was a reduction of plasma iron and
ferritin between two and five 5 months of age, which is con-
sistent with the physiologic destruction of red blood cells dur-
ing the first three months of life. The placebo group showed
an increase in the prevalence of iron deficiency from less than
1% at two months of age to more than 30% by 12 months of
age. The children who received only malaria chemoprophy-
laxis had similar prevalences of iron deficiency than those
receiving no intervention. At all surveys after the intervention
started, the frequency of iron deficiency was lower in the two
groups receiving iron supplementation compared with the
placebo-placebo group. Children who had received iron for
four months during the first year of life had a lower (64−92%)
risk of iron deficiency than those who did not (Table 3). There
were no significant differences in the frequency of iron defi-
ciency between the two iron-supplemented groups.
Red blood cell indices and iron parameters by intervention
group and age during the first year of life. Table 1 shows the
values of biochemical markers of iron status and quantitative
red blood cell indices by treatment group and survey during
the intervention period. Plasma iron concentrations were
higher during supplementation than after supplementation.
Ferritin and transferrin concentrations remained significantly
improved up to and including the 12 month survey. Red blood
cell indices (MCV, MCH, and MCHC) were consistently
higher in the two groups receiving iron supplements than in
those infants who did not. The beneficial effects of iron
supplementation between two and six months of age on
MCV, MCH, and MCHC were also maintained until one year
of age.
The prevalence of microcytosis was highest at five months
of age (69%), decreasing progressively up to 12 months of age
(45%). Children on iron supplements had lower prevalence of
microcytosis at all ages than those in the placebo-placebo
group. The majority of children had hypochromia from five
months of age (89%), with a peak prevalence at 12 months of
age in all groups (96%). Hypochromia was less frequent in
children who received iron supplements compared with the
placebo-placebo group, except at five months when only the
group receiving iron alone had a lower prevalence of hypo-
chromia compared with the placebo-placebo group, and this
was of borderline significance (P  0.06) (Table 2).
The proportion of children with increased reticulocyte
counts was higher in the two groups receiving iron supple-
ments compared with the groups that did not receive iron,
although the difference did not reach statistical significance
(39.1% and 38.5% in the IP and DI groups, respectively, com-
pared with 13.0% and 32.0% in the PP and DP groups, re-
spectively; P  0.165). Neither iron nor malaria chemopro-
phylaxis with Deltaprim were associated with side effects as
assessed through morbidity and analytical surveillance.3
DISCUSSION
In this area of sub-Saharan Africa, there is a high preva-
lence of iron deficiency even in infants less than six months of
age. The prevalence of iron deficiency in our study increased
with age in all intervention groups. More than one-third of
children who did not receive iron supplements were iron de-
ficient by one year of age. However, this may still be an
underestimate judging by the prevalence of microcytosis and
hypochromia. These high frequencies of both microcytosis
and hypochromia may be partly explained by the high fre-
quency of -thalassemia found in these children (44.3% and
10.3% for heterozygous [-/] and homozygous [-/-/], re-
spectively, Mayor A, unpublished data), which was equally
distributed between the four intervention groups (P  0.86).
The recognized difficulties in assessing iron status in popula-
tions exposed to malaria may have contributed to this under-
estimation in the frequency of iron deficiency.12,21−23 A reli-
able, non-invasive tool for the assessment of iron deficiency in
these populations remains elusive, since malaria infection af-
fects all conventional laboratory tests of iron status. Measure-
ment of soluble transferrin receptors has been proposed as an
alternative test to overcome this problem.23 However, a re-
cent study has showed that this is also modified by malaria
parasitaemia.24
Iron supplements were started at two months of age. At the
time of the study, there were no clear recommendations re-
garding iron supplementation for the prevention of iron de-
ficiency in infants in malaria-endemic areas. As in many other
malaria-endemic regions, the prevalence of anemia is very
high during the first year of life. This, together with the high
prevalence of maternal anemia and of low birth weight, led us
to start the administration of iron supplements earlier than
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usually recommended for non-malaria-endemic areas. The
duration of supplementation was chosen to maximize compli-
ance. Iron supplementation for a relatively short period of
time, between two and six months of age, resulted in signifi-
cant improvements in iron status sustained at least up to one
year of age. A higher proportion of children with increased
reticulocyte counts at 12 months of age in the groups who had
received iron supplements compared with the ones who did
not suggests a more active erythroid marrow in those chil-
dren. Taken together with the efficacy results previously re-
ported,3 these results suggest that short-term iron supplemen-
tation regimens improve iron status in a clinically and hema-
tologically significant way and for a prolonged period.
Furthermore, it is possible that this regimen of iron supple-
mentation might be delivered at the time of existing health
contacts, such as with the Expanded Program of Immuniza-
tion.
Long-term (18–22 months) iron supplementation regimens
have been proposed for the prevention of iron deficiency in
children living in areas where anemia is highly prevalent.7
This recommendation is based on empirical hematologic ben-
efits. However, it remains unclear whether such long-term
supplementation might increase the risk of malaria infection.
In addition, the effectiveness of this intervention clearly relies
on good compliance, as well as on an available and sustain-
able supply of iron syrup and an effective means of delivering
the supplements to the target group.
Finally, the results of this randomized, placebo-controlled
trial do not suggest that malaria contributed to the high
prevalence of iron deficiency. Children who received malaria
chemoprophylaxis were partially protected against malaria in-
fection, as was shown by a statistically significantly lower in-
cidence of malaria episodes in this group compared with those
not receiving antimalarial prophylaxis.3 However, they had
similar prevalences of iron deficiency at all surveys as the
children who were not protected against malaria and who did
not receive iron supplements. This is unlikely to be a chance
finding because a similar pattern was observed for microcy-
tosis and hypochromia, neither of which were included in the
definition of iron deficiency. The possibility that dapsone-
related hemolysis worsened hematologic parameters in chil-
dren receiving chemoprophylaxis is excluded by the lack of a
difference in red blood cell indices between the two iron-
supplemented groups.
In summary, this study shows that a potentially practical
iron supplementation regimen between two and six months of
age produced significant and sustained improvements in iron
status at least up to the end of the first year of life. Although
iron deficiency was not eliminated in study children, its preva-
lence was dramatically reduced. Studies are warranted to as-
sess the longer-term effects of this approach to iron supple-
mentation and to assess the feasibility of delivering supple-
ments to the target group at routine health contacts.
Received May 29, 2003. Accepted for publication February 18, 2004.
Acknowledgments: We are indebted to the parents and guardians of
the children involved in the study. We thank the staff of the Ifakara
Health Research and Development Centre and the St. Francis Des-
ignated District Hospital, Dr. F. Lwilla, and the District Health Man-
agement Team for their support in facilitating the study team to carry
out the study. We are also grateful to Dr. R. Fernandez and the staff
of the Nuclear Medicine Laboratory of the Hospital Clinic for testing
the plasma ferritins and to Professor Alan Fleming for his comments
on the manuscript.
Financial support: This study was supported by grants from the
UNDP/World Bank/World Health Organization Special Program for
Research and Training in Tropical Diseases, the Spanish Agency for
International Cooperation, and the Fondo de Investigaciones Sani-
tarias. The Ifakara Health Research and Development Centre and St.
Francis Designated District Hospital receive funding from the Swiss
Agency for Development and Cooperation and the Government of
Tanzania.
Author’s addresses: Clara Menendez, David Schellenberg, Llorenc¸
Quinto, Luisa Alvarez, John J. Aponte, and Pedro L. Alonso, Center
for International Health, Hospital Clinic/University of Barcelona,
Villarroel 170, E-08036, Barcelona, Spain, Telephone: 34-93-227-
5706, Fax: 34-93-451-5272, E-mails: cmenende@medicina.ub.es,
DMSchellenberg@aol.com, llquinto@medicina.ub.es, lalvarez@clinic.
ub.es, Japonte@medicina.ub.es, and alonso@medicina.ub.es. Elizeus
Kahigwa, Ifakara Research and Development Center, Ifakara Tanzania
and St. Francis District Designated Hospital, Ifakara, Tanzania. E-mail:
ekahigwa@yahoo.com.
REFERENCES
1. Fleming AF, 1981. Iron deficiency in the tropics. Clin Haematol
11: 365–388.
2. Schellenberg D, Menendez C, Kahigwa E, Font F, Galindo C,
Acosta C, Armstrong-Schellenberg J, Aponte JJ, Kimario J,
Urassa H, Mshinda H, Tanner M, Alonso P, 1999. African
children with malaria in an area of intense Plasmodium falci-
parum transmission: features on admission to the hospital and
risk factors for death. Am J Trop Med Hyg 61: 431–438.
3. Menendez, C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font
F, Acosta CJ, Schellenberg DS, Galindo C M, Kimario J,
Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso
PL, 1997. Randomised placebo-controlled trial of iron supple-
mentation and malaria chemoprophylaxis for prevention of
severe anemia and malaria in Tanzanian infants. Lancet 350:
844–850.
4. Provan D, 1999. Mechanisms and management of iron deficiency
anemia. Br J Haematol 105: 19–26.
TABLE 3
Odds ratio of iron deficiency at each age by intervention group*
Intervention group
Age (months)
2 5 8 12
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
P-P 1 1 1 1
D-P 1.0 (0.1, 15.9) 1.3 (0.7, 2.4) 0.9 (0.5, 1.6) 0.9 (0.5, 1.5)
I-P –† 0.1‡ (0.0, 0.4) 0.2§ (0.1, 0.5) 0.4‡ (0.2, 0.6)
I-D 1.0 (0.1, 15.9) 0.1‡ (0.0, 0.4) 0.2§ (0.1, 0.4) 0.1§ (0.1, 0.3)
* OR  odds ratio; CI  confidence interval; P-P  placebo-placebo; D-P  deltaprim-placebo; I-P  iron-placebo; I-D  iron-deltaprim.
† No events.
‡ P < 0.01.
§ P < 0.001.
IRON SUPPLEMENTATION FOR INFANTS IN MALARIA-ENDEMIC AREAS 439
5. Oski FA, 1993. Current concepts: iron deficiency in infancy and
childhood. N Eng J Med 329: 190–193.
6. Brabin B, 1992. Fetal anemia in malarious areas: its causes and
significance. Ann Trop Paediat 12: 303–310.
7. Stoltzfus R, Dreyfuss ML, 1998. Guidelines for the Use of Iron
Supplements to Prevent and Treat Iron Deficiency Anemia.
Washington, DC: INACG/WHO/UNICEF, ILSI Press.
8. Bojang KA, Palmer A, Van Hensbroek MB, Banya WAS,
Greenwood BM, 1997. Management of severe malarial anemia
in Gambian children. Trans R Soc Trop Med Hyg 91: 557–561.
9. Van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L,
Dackour R, Phillips C, Greenwood BM, 1995. Iron, but not
folic acid, combined with effective antimalarial therapy pro-
motes haematological recovery in African children after acute
falciparum malaria. Trans R Soc Trop Med Hyg 89: 672–676.
10. Willcox MC, Bjorkman A, Brohult J, 1985. The effect of persis-
tent malarial infection on haemoglobin A2 levels in Liberian
children. Trans R Soc Trop Med Hyg 79: 242–245.
11. Molyneux MES, Looareesuwan IS, Menzies SL, Grainger SL,
Phillips RE, Wattanagoon Y, Thompson RP, Warrell DA,
1989. Reduced hepatic blood flow and intestinal malabsorption
in severe falciparum malaria. Am J Trop Med Hyg 40: 470–476.
12. Filteau SM, Tomkins AM, 1994. Micronutrients and tropical in-
fections. Trans R Soc Trop Med Hyg 88: 1−3.
13. Abdalla SH, 1990. Iron and folate status in Gambian children
with malaria. Ann Trop Paediat 10: 265–272.
14. Weinberg ED, 1978. Iron and infection. Microbiol Rev 42: 45–66.
15. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P,
Muwissen J, Lyimo E, Takken W, Teuscher T, Tanner M,
1993. Absence of seasonal variation in malaria parasitaemia in
an area of intense seasonal transmission. Acta Trop 54: 55–72.
16. Schellenberg D, Aponte J, Kahigwa E, Mshinda H, Tanner M,
Menendez C, Alonso PL, 2003. The incidence of clinical ma-
laria detected by active case detection in children in Ifakara,
southern Tanzania. Trans R Soc Trop Med Hyg 97: 1–8.
17. Gascon J, Vargas M, Schellenberg D, Urassa H, Casals C, Ka-
higwa E, Aponte JJ, Mshinda H, Vila J, 2000. Diarrhea in
children under 5 years of age from Ifakara, Tanzania: a case-
control study. J Clin Microbiol 38: 4459–4462.
18. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H,
Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J,
Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss
N, Hayes R, Kitua A, Lopez MC, Kilama WC, Teuscher T,
Tanner M, 1994. Randomised trial of efficacy of SPf66 vaccine
against Plasmodium falciparum malaria in children in southern
Tanzania. Lancet 344: 1175–1181.
19. Meites S, 1989. Reference (normal) values. Meites S, ed. Pediatric
Clinical Chemistry. Third edition. Washington, DC: Amercian
Association for Clinical Chemistry Press, 119−120.
20. Dacie JV, Lewis SM, 1995. Reference ranges and normal values.
Dacie JV, Lewis SM, eds. Practical Haematology. Eighth edi-
tion. Edinburgh: Churchill Livingstone, 17.
21. Das BS, Thurnham DI, Das DB, 1997. Influence of malaria on
markers of iron status in children: implications for interpreting
iron status in malaria-endemic communities. Br J Nutr 78: 751–
760.
22. Ayatse JO, Ekanem EE, 1994. Plasmodium falciparum malaria:
its effects on some haematological parameters in normal and
sickle cell Nigerian children. Trop Med Parasitol 45: 219–222.
23. Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD,
1991. Serum transferrin receptor distinguishes the anemia of
chronic disease from iron deficiency anemia. J Lab Clin Med
119: 385–390.
24. Menendez C, Quinto LL, Kahigwa E, Alvarez L, Fernandez R,
Gimenez N, Schellenberg D, Tanner M, Alonso PL, 2001. Ma-
laria infection increases soluble transferrin receptors in Tan-
zanian infants. Am J Trop Med Hyg 65: 138–142.
MENENDEZ AND OTHERS440
